nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—NR1I2—Erlotinib—pancreatic cancer	0.439	0.54	CbGbCtD
Rifaximin—NR1I2—Docetaxel—pancreatic cancer	0.291	0.357	CbGbCtD
Rifaximin—CYP3A4—Tamoxifen—pancreatic cancer	0.0202	0.0249	CbGbCtD
Rifaximin—CYP3A4—Erlotinib—pancreatic cancer	0.0172	0.0212	CbGbCtD
Rifaximin—CYP3A4—Irinotecan—pancreatic cancer	0.0155	0.0191	CbGbCtD
Rifaximin—CYP3A4—Docetaxel—pancreatic cancer	0.0114	0.014	CbGbCtD
Rifaximin—CYP3A4—Sunitinib—pancreatic cancer	0.0113	0.0139	CbGbCtD
Rifaximin—CYP3A4—Doxorubicin—pancreatic cancer	0.00849	0.0104	CbGbCtD
Rifaximin—Nausea—Tamoxifen—pancreatic cancer	0.000199	0.00107	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000199	0.00107	CcSEcCtD
Rifaximin—Fatigue—Gemcitabine—pancreatic cancer	0.000199	0.00107	CcSEcCtD
Rifaximin—Pain—Gemcitabine—pancreatic cancer	0.000197	0.00106	CcSEcCtD
Rifaximin—Constipation—Gemcitabine—pancreatic cancer	0.000197	0.00106	CcSEcCtD
Rifaximin—Nausea—Erlotinib—pancreatic cancer	0.000197	0.00106	CcSEcCtD
Rifaximin—Decreased appetite—Fluorouracil—pancreatic cancer	0.000197	0.00106	CcSEcCtD
Rifaximin—Diarrhoea—Sunitinib—pancreatic cancer	0.000197	0.00106	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000196	0.00105	CcSEcCtD
Rifaximin—Abdominal distension—Epirubicin—pancreatic cancer	0.000196	0.00105	CcSEcCtD
Rifaximin—Feeling abnormal—Irinotecan—pancreatic cancer	0.000195	0.00105	CcSEcCtD
Rifaximin—Dysphagia—Epirubicin—pancreatic cancer	0.000194	0.00104	CcSEcCtD
Rifaximin—Back pain—Docetaxel—pancreatic cancer	0.000194	0.00104	CcSEcCtD
Rifaximin—Pain—Fluorouracil—pancreatic cancer	0.000194	0.00104	CcSEcCtD
Rifaximin—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000194	0.00104	CcSEcCtD
Rifaximin—Dehydration—Doxorubicin—pancreatic cancer	0.000193	0.00104	CcSEcCtD
Rifaximin—Muscle spasms—Docetaxel—pancreatic cancer	0.000193	0.00104	CcSEcCtD
Rifaximin—Dizziness—Sunitinib—pancreatic cancer	0.00019	0.00102	CcSEcCtD
Rifaximin—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00019	0.00102	CcSEcCtD
Rifaximin—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.00019	0.00102	CcSEcCtD
Rifaximin—Body temperature increased—Irinotecan—pancreatic cancer	0.000187	0.00101	CcSEcCtD
Rifaximin—Abdominal pain—Irinotecan—pancreatic cancer	0.000187	0.00101	CcSEcCtD
Rifaximin—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000187	0.00101	CcSEcCtD
Rifaximin—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000187	0.00101	CcSEcCtD
Rifaximin—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000186	0.001	CcSEcCtD
Rifaximin—Anaemia—Docetaxel—pancreatic cancer	0.000185	0.000997	CcSEcCtD
Rifaximin—Vomiting—Sunitinib—pancreatic cancer	0.000183	0.000983	CcSEcCtD
Rifaximin—Body temperature increased—Gemcitabine—pancreatic cancer	0.000182	0.000981	CcSEcCtD
Rifaximin—Neutropenia—Epirubicin—pancreatic cancer	0.000182	0.000977	CcSEcCtD
Rifaximin—Dysuria—Epirubicin—pancreatic cancer	0.000182	0.000977	CcSEcCtD
Rifaximin—Rash—Sunitinib—pancreatic cancer	0.000181	0.000975	CcSEcCtD
Rifaximin—Dermatitis—Sunitinib—pancreatic cancer	0.000181	0.000974	CcSEcCtD
Rifaximin—Abdominal distension—Doxorubicin—pancreatic cancer	0.000181	0.000973	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000181	0.000971	CcSEcCtD
Rifaximin—Urticaria—Fluorouracil—pancreatic cancer	0.00018	0.000969	CcSEcCtD
Rifaximin—Headache—Sunitinib—pancreatic cancer	0.00018	0.000969	CcSEcCtD
Rifaximin—Syncope—Docetaxel—pancreatic cancer	0.00018	0.000968	CcSEcCtD
Rifaximin—Dysphagia—Doxorubicin—pancreatic cancer	0.00018	0.000966	CcSEcCtD
Rifaximin—Pollakiuria—Epirubicin—pancreatic cancer	0.000179	0.000965	CcSEcCtD
Rifaximin—Body temperature increased—Fluorouracil—pancreatic cancer	0.000179	0.000964	CcSEcCtD
Rifaximin—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000177	0.000953	CcSEcCtD
Rifaximin—Weight increased—Epirubicin—pancreatic cancer	0.000177	0.000951	CcSEcCtD
Rifaximin—Loss of consciousness—Docetaxel—pancreatic cancer	0.000176	0.000948	CcSEcCtD
Rifaximin—Weight decreased—Epirubicin—pancreatic cancer	0.000176	0.000945	CcSEcCtD
Rifaximin—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000175	0.000942	CcSEcCtD
Rifaximin—Cough—Docetaxel—pancreatic cancer	0.000175	0.000941	CcSEcCtD
Rifaximin—Hypersensitivity—Irinotecan—pancreatic cancer	0.000175	0.000938	CcSEcCtD
Rifaximin—Pneumonia—Epirubicin—pancreatic cancer	0.000174	0.000937	CcSEcCtD
Rifaximin—Infestation—Epirubicin—pancreatic cancer	0.000173	0.000931	CcSEcCtD
Rifaximin—Infestation NOS—Epirubicin—pancreatic cancer	0.000173	0.000931	CcSEcCtD
Rifaximin—Myalgia—Docetaxel—pancreatic cancer	0.000171	0.000919	CcSEcCtD
Rifaximin—Chest pain—Docetaxel—pancreatic cancer	0.000171	0.000919	CcSEcCtD
Rifaximin—Arthralgia—Docetaxel—pancreatic cancer	0.000171	0.000919	CcSEcCtD
Rifaximin—Nausea—Sunitinib—pancreatic cancer	0.000171	0.000919	CcSEcCtD
Rifaximin—Asthenia—Irinotecan—pancreatic cancer	0.00017	0.000914	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.00017	0.000912	CcSEcCtD
Rifaximin—Neutropenia—Doxorubicin—pancreatic cancer	0.000168	0.000904	CcSEcCtD
Rifaximin—Dysuria—Doxorubicin—pancreatic cancer	0.000168	0.000904	CcSEcCtD
Rifaximin—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000167	0.000899	CcSEcCtD
Rifaximin—Dry mouth—Docetaxel—pancreatic cancer	0.000167	0.000898	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000167	0.000898	CcSEcCtD
Rifaximin—Pollakiuria—Doxorubicin—pancreatic cancer	0.000166	0.000893	CcSEcCtD
Rifaximin—Asthenia—Gemcitabine—pancreatic cancer	0.000166	0.00089	CcSEcCtD
Rifaximin—Haematuria—Epirubicin—pancreatic cancer	0.000165	0.000888	CcSEcCtD
Rifaximin—Confusional state—Docetaxel—pancreatic cancer	0.000165	0.000888	CcSEcCtD
Rifaximin—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000164	0.000882	CcSEcCtD
Rifaximin—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000164	0.000881	CcSEcCtD
Rifaximin—Weight increased—Doxorubicin—pancreatic cancer	0.000164	0.000879	CcSEcCtD
Rifaximin—Epistaxis—Epirubicin—pancreatic cancer	0.000163	0.000878	CcSEcCtD
Rifaximin—Pruritus—Gemcitabine—pancreatic cancer	0.000163	0.000878	CcSEcCtD
Rifaximin—Infection—Docetaxel—pancreatic cancer	0.000163	0.000875	CcSEcCtD
Rifaximin—Weight decreased—Doxorubicin—pancreatic cancer	0.000163	0.000874	CcSEcCtD
Rifaximin—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000162	0.000872	CcSEcCtD
Rifaximin—Diarrhoea—Irinotecan—pancreatic cancer	0.000162	0.000872	CcSEcCtD
Rifaximin—Pneumonia—Doxorubicin—pancreatic cancer	0.000161	0.000867	CcSEcCtD
Rifaximin—Shock—Docetaxel—pancreatic cancer	0.000161	0.000866	CcSEcCtD
Rifaximin—Nervous system disorder—Docetaxel—pancreatic cancer	0.000161	0.000864	CcSEcCtD
Rifaximin—Pruritus—Fluorouracil—pancreatic cancer	0.000161	0.000863	CcSEcCtD
Rifaximin—Infestation—Doxorubicin—pancreatic cancer	0.00016	0.000862	CcSEcCtD
Rifaximin—Infestation NOS—Doxorubicin—pancreatic cancer	0.00016	0.000862	CcSEcCtD
Rifaximin—Skin disorder—Docetaxel—pancreatic cancer	0.000159	0.000855	CcSEcCtD
Rifaximin—Diarrhoea—Gemcitabine—pancreatic cancer	0.000158	0.000849	CcSEcCtD
Rifaximin—Dizziness—Irinotecan—pancreatic cancer	0.000157	0.000842	CcSEcCtD
Rifaximin—Haemoglobin—Epirubicin—pancreatic cancer	0.000156	0.00084	CcSEcCtD
Rifaximin—Anorexia—Docetaxel—pancreatic cancer	0.000156	0.000839	CcSEcCtD
Rifaximin—Rhinitis—Epirubicin—pancreatic cancer	0.000156	0.000838	CcSEcCtD
Rifaximin—Haemorrhage—Epirubicin—pancreatic cancer	0.000155	0.000836	CcSEcCtD
Rifaximin—Diarrhoea—Fluorouracil—pancreatic cancer	0.000155	0.000835	CcSEcCtD
Rifaximin—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000155	0.000832	CcSEcCtD
Rifaximin—Pharyngitis—Epirubicin—pancreatic cancer	0.000154	0.00083	CcSEcCtD
Rifaximin—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000154	0.000826	CcSEcCtD
Rifaximin—Oedema peripheral—Epirubicin—pancreatic cancer	0.000153	0.000824	CcSEcCtD
Rifaximin—Hypotension—Docetaxel—pancreatic cancer	0.000153	0.000823	CcSEcCtD
Rifaximin—Haematuria—Doxorubicin—pancreatic cancer	0.000153	0.000822	CcSEcCtD
Rifaximin—Urethral disorder—Epirubicin—pancreatic cancer	0.000152	0.000819	CcSEcCtD
Rifaximin—Epistaxis—Doxorubicin—pancreatic cancer	0.000151	0.000813	CcSEcCtD
Rifaximin—Vomiting—Irinotecan—pancreatic cancer	0.000151	0.00081	CcSEcCtD
Rifaximin—Dizziness—Fluorouracil—pancreatic cancer	0.00015	0.000807	CcSEcCtD
Rifaximin—Rash—Irinotecan—pancreatic cancer	0.000149	0.000803	CcSEcCtD
Rifaximin—Dermatitis—Irinotecan—pancreatic cancer	0.000149	0.000802	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000149	0.000802	CcSEcCtD
Rifaximin—Headache—Irinotecan—pancreatic cancer	0.000148	0.000798	CcSEcCtD
Rifaximin—Insomnia—Docetaxel—pancreatic cancer	0.000148	0.000796	CcSEcCtD
Rifaximin—Vomiting—Gemcitabine—pancreatic cancer	0.000147	0.000789	CcSEcCtD
Rifaximin—Dyspnoea—Docetaxel—pancreatic cancer	0.000146	0.000785	CcSEcCtD
Rifaximin—Rash—Gemcitabine—pancreatic cancer	0.000145	0.000782	CcSEcCtD
Rifaximin—Dermatitis—Gemcitabine—pancreatic cancer	0.000145	0.000782	CcSEcCtD
Rifaximin—Tinnitus—Epirubicin—pancreatic cancer	0.000145	0.000779	CcSEcCtD
Rifaximin—Haemoglobin—Doxorubicin—pancreatic cancer	0.000145	0.000777	CcSEcCtD
Rifaximin—Headache—Gemcitabine—pancreatic cancer	0.000145	0.000777	CcSEcCtD
Rifaximin—Flushing—Epirubicin—pancreatic cancer	0.000144	0.000776	CcSEcCtD
Rifaximin—Vomiting—Fluorouracil—pancreatic cancer	0.000144	0.000776	CcSEcCtD
Rifaximin—Rhinitis—Doxorubicin—pancreatic cancer	0.000144	0.000775	CcSEcCtD
Rifaximin—Haemorrhage—Doxorubicin—pancreatic cancer	0.000144	0.000774	CcSEcCtD
Rifaximin—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000143	0.00077	CcSEcCtD
Rifaximin—Rash—Fluorouracil—pancreatic cancer	0.000143	0.000769	CcSEcCtD
Rifaximin—Dermatitis—Fluorouracil—pancreatic cancer	0.000143	0.000769	CcSEcCtD
Rifaximin—Pharyngitis—Doxorubicin—pancreatic cancer	0.000143	0.000768	CcSEcCtD
Rifaximin—Decreased appetite—Docetaxel—pancreatic cancer	0.000142	0.000765	CcSEcCtD
Rifaximin—Headache—Fluorouracil—pancreatic cancer	0.000142	0.000764	CcSEcCtD
Rifaximin—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000142	0.000764	CcSEcCtD
Rifaximin—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000142	0.000762	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000141	0.00076	CcSEcCtD
Rifaximin—Fatigue—Docetaxel—pancreatic cancer	0.000141	0.000759	CcSEcCtD
Rifaximin—Angiopathy—Epirubicin—pancreatic cancer	0.000141	0.000758	CcSEcCtD
Rifaximin—Urethral disorder—Doxorubicin—pancreatic cancer	0.000141	0.000758	CcSEcCtD
Rifaximin—Nausea—Irinotecan—pancreatic cancer	0.000141	0.000757	CcSEcCtD
Rifaximin—Mediastinal disorder—Epirubicin—pancreatic cancer	0.00014	0.000753	CcSEcCtD
Rifaximin—Pain—Docetaxel—pancreatic cancer	0.00014	0.000753	CcSEcCtD
Rifaximin—Constipation—Docetaxel—pancreatic cancer	0.00014	0.000753	CcSEcCtD
Rifaximin—Nausea—Gemcitabine—pancreatic cancer	0.000137	0.000737	CcSEcCtD
Rifaximin—Mental disorder—Epirubicin—pancreatic cancer	0.000136	0.000732	CcSEcCtD
Rifaximin—Malnutrition—Epirubicin—pancreatic cancer	0.000135	0.000728	CcSEcCtD
Rifaximin—Feeling abnormal—Docetaxel—pancreatic cancer	0.000135	0.000726	CcSEcCtD
Rifaximin—Nausea—Fluorouracil—pancreatic cancer	0.000135	0.000725	CcSEcCtD
Rifaximin—Tinnitus—Doxorubicin—pancreatic cancer	0.000134	0.000721	CcSEcCtD
Rifaximin—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000134	0.00072	CcSEcCtD
Rifaximin—Flushing—Doxorubicin—pancreatic cancer	0.000134	0.000718	CcSEcCtD
Rifaximin—Flatulence—Epirubicin—pancreatic cancer	0.000133	0.000717	CcSEcCtD
Rifaximin—Back pain—Epirubicin—pancreatic cancer	0.000131	0.000704	CcSEcCtD
Rifaximin—Angiopathy—Doxorubicin—pancreatic cancer	0.000131	0.000702	CcSEcCtD
Rifaximin—Muscle spasms—Epirubicin—pancreatic cancer	0.00013	0.0007	CcSEcCtD
Rifaximin—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.00013	0.000697	CcSEcCtD
Rifaximin—Abdominal pain—Docetaxel—pancreatic cancer	0.000129	0.000696	CcSEcCtD
Rifaximin—Body temperature increased—Docetaxel—pancreatic cancer	0.000129	0.000696	CcSEcCtD
Rifaximin—Mental disorder—Doxorubicin—pancreatic cancer	0.000126	0.000678	CcSEcCtD
Rifaximin—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000126	0.000675	CcSEcCtD
Rifaximin—Malnutrition—Doxorubicin—pancreatic cancer	0.000125	0.000673	CcSEcCtD
Rifaximin—Anaemia—Epirubicin—pancreatic cancer	0.000125	0.000673	CcSEcCtD
Rifaximin—Flatulence—Doxorubicin—pancreatic cancer	0.000123	0.000664	CcSEcCtD
Rifaximin—Malaise—Epirubicin—pancreatic cancer	0.000122	0.000656	CcSEcCtD
Rifaximin—Vertigo—Epirubicin—pancreatic cancer	0.000122	0.000654	CcSEcCtD
Rifaximin—Syncope—Epirubicin—pancreatic cancer	0.000121	0.000653	CcSEcCtD
Rifaximin—Back pain—Doxorubicin—pancreatic cancer	0.000121	0.000651	CcSEcCtD
Rifaximin—Hypersensitivity—Docetaxel—pancreatic cancer	0.000121	0.000649	CcSEcCtD
Rifaximin—Muscle spasms—Doxorubicin—pancreatic cancer	0.00012	0.000647	CcSEcCtD
Rifaximin—Loss of consciousness—Epirubicin—pancreatic cancer	0.000119	0.00064	CcSEcCtD
Rifaximin—Cough—Epirubicin—pancreatic cancer	0.000118	0.000635	CcSEcCtD
Rifaximin—Asthenia—Docetaxel—pancreatic cancer	0.000117	0.000632	CcSEcCtD
Rifaximin—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000116	0.000625	CcSEcCtD
Rifaximin—Pruritus—Docetaxel—pancreatic cancer	0.000116	0.000623	CcSEcCtD
Rifaximin—Anaemia—Doxorubicin—pancreatic cancer	0.000116	0.000622	CcSEcCtD
Rifaximin—Chest pain—Epirubicin—pancreatic cancer	0.000115	0.00062	CcSEcCtD
Rifaximin—Myalgia—Epirubicin—pancreatic cancer	0.000115	0.00062	CcSEcCtD
Rifaximin—Arthralgia—Epirubicin—pancreatic cancer	0.000115	0.00062	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000114	0.000615	CcSEcCtD
Rifaximin—Discomfort—Epirubicin—pancreatic cancer	0.000114	0.000612	CcSEcCtD
Rifaximin—Malaise—Doxorubicin—pancreatic cancer	0.000113	0.000607	CcSEcCtD
Rifaximin—Dry mouth—Epirubicin—pancreatic cancer	0.000113	0.000606	CcSEcCtD
Rifaximin—Vertigo—Doxorubicin—pancreatic cancer	0.000113	0.000605	CcSEcCtD
Rifaximin—Syncope—Doxorubicin—pancreatic cancer	0.000112	0.000604	CcSEcCtD
Rifaximin—Diarrhoea—Docetaxel—pancreatic cancer	0.000112	0.000602	CcSEcCtD
Rifaximin—Confusional state—Epirubicin—pancreatic cancer	0.000111	0.000599	CcSEcCtD
Rifaximin—Anaphylactic shock—Epirubicin—pancreatic cancer	0.00011	0.000594	CcSEcCtD
Rifaximin—Loss of consciousness—Doxorubicin—pancreatic cancer	0.00011	0.000592	CcSEcCtD
Rifaximin—Infection—Epirubicin—pancreatic cancer	0.00011	0.00059	CcSEcCtD
Rifaximin—Cough—Doxorubicin—pancreatic cancer	0.000109	0.000588	CcSEcCtD
Rifaximin—Shock—Epirubicin—pancreatic cancer	0.000109	0.000584	CcSEcCtD
Rifaximin—Nervous system disorder—Epirubicin—pancreatic cancer	0.000108	0.000582	CcSEcCtD
Rifaximin—Dizziness—Docetaxel—pancreatic cancer	0.000108	0.000582	CcSEcCtD
Rifaximin—Skin disorder—Epirubicin—pancreatic cancer	0.000107	0.000577	CcSEcCtD
Rifaximin—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000107	0.000574	CcSEcCtD
Rifaximin—Myalgia—Doxorubicin—pancreatic cancer	0.000107	0.000573	CcSEcCtD
Rifaximin—Chest pain—Doxorubicin—pancreatic cancer	0.000107	0.000573	CcSEcCtD
Rifaximin—Arthralgia—Doxorubicin—pancreatic cancer	0.000107	0.000573	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000106	0.000569	CcSEcCtD
Rifaximin—Discomfort—Doxorubicin—pancreatic cancer	0.000105	0.000566	CcSEcCtD
Rifaximin—Anorexia—Epirubicin—pancreatic cancer	0.000105	0.000566	CcSEcCtD
Rifaximin—Dry mouth—Doxorubicin—pancreatic cancer	0.000104	0.000561	CcSEcCtD
Rifaximin—Vomiting—Docetaxel—pancreatic cancer	0.000104	0.00056	CcSEcCtD
Rifaximin—Rash—Docetaxel—pancreatic cancer	0.000103	0.000555	CcSEcCtD
Rifaximin—Hypotension—Epirubicin—pancreatic cancer	0.000103	0.000555	CcSEcCtD
Rifaximin—Dermatitis—Docetaxel—pancreatic cancer	0.000103	0.000555	CcSEcCtD
Rifaximin—Confusional state—Doxorubicin—pancreatic cancer	0.000103	0.000554	CcSEcCtD
Rifaximin—Headache—Docetaxel—pancreatic cancer	0.000103	0.000552	CcSEcCtD
Rifaximin—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000102	0.00055	CcSEcCtD
Rifaximin—Infection—Doxorubicin—pancreatic cancer	0.000102	0.000546	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000101	0.000541	CcSEcCtD
Rifaximin—Shock—Doxorubicin—pancreatic cancer	0.000101	0.000541	CcSEcCtD
Rifaximin—Nervous system disorder—Doxorubicin—pancreatic cancer	0.0001	0.000539	CcSEcCtD
Rifaximin—Insomnia—Epirubicin—pancreatic cancer	9.99e-05	0.000537	CcSEcCtD
Rifaximin—Skin disorder—Doxorubicin—pancreatic cancer	9.93e-05	0.000534	CcSEcCtD
Rifaximin—Hyperhidrosis—Doxorubicin—pancreatic cancer	9.88e-05	0.000531	CcSEcCtD
Rifaximin—Dyspnoea—Epirubicin—pancreatic cancer	9.85e-05	0.00053	CcSEcCtD
Rifaximin—Anorexia—Doxorubicin—pancreatic cancer	9.74e-05	0.000524	CcSEcCtD
Rifaximin—Nausea—Docetaxel—pancreatic cancer	9.73e-05	0.000523	CcSEcCtD
Rifaximin—Decreased appetite—Epirubicin—pancreatic cancer	9.6e-05	0.000516	CcSEcCtD
Rifaximin—Hypotension—Doxorubicin—pancreatic cancer	9.55e-05	0.000514	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Epirubicin—pancreatic cancer	9.54e-05	0.000513	CcSEcCtD
Rifaximin—Fatigue—Epirubicin—pancreatic cancer	9.52e-05	0.000512	CcSEcCtD
Rifaximin—Constipation—Epirubicin—pancreatic cancer	9.45e-05	0.000508	CcSEcCtD
Rifaximin—Pain—Epirubicin—pancreatic cancer	9.45e-05	0.000508	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	9.31e-05	0.000501	CcSEcCtD
Rifaximin—Insomnia—Doxorubicin—pancreatic cancer	9.24e-05	0.000497	CcSEcCtD
Rifaximin—Dyspnoea—Doxorubicin—pancreatic cancer	9.11e-05	0.00049	CcSEcCtD
Rifaximin—Feeling abnormal—Epirubicin—pancreatic cancer	9.1e-05	0.000489	CcSEcCtD
Rifaximin—Gastrointestinal pain—Epirubicin—pancreatic cancer	9.03e-05	0.000486	CcSEcCtD
Rifaximin—Decreased appetite—Doxorubicin—pancreatic cancer	8.88e-05	0.000478	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	8.82e-05	0.000474	CcSEcCtD
Rifaximin—Fatigue—Doxorubicin—pancreatic cancer	8.81e-05	0.000474	CcSEcCtD
Rifaximin—Urticaria—Epirubicin—pancreatic cancer	8.77e-05	0.000472	CcSEcCtD
Rifaximin—Constipation—Doxorubicin—pancreatic cancer	8.74e-05	0.00047	CcSEcCtD
Rifaximin—Pain—Doxorubicin—pancreatic cancer	8.74e-05	0.00047	CcSEcCtD
Rifaximin—Abdominal pain—Epirubicin—pancreatic cancer	8.73e-05	0.00047	CcSEcCtD
Rifaximin—Body temperature increased—Epirubicin—pancreatic cancer	8.73e-05	0.00047	CcSEcCtD
Rifaximin—Feeling abnormal—Doxorubicin—pancreatic cancer	8.42e-05	0.000453	CcSEcCtD
Rifaximin—Gastrointestinal pain—Doxorubicin—pancreatic cancer	8.36e-05	0.000449	CcSEcCtD
Rifaximin—Hypersensitivity—Epirubicin—pancreatic cancer	8.14e-05	0.000438	CcSEcCtD
Rifaximin—Urticaria—Doxorubicin—pancreatic cancer	8.12e-05	0.000437	CcSEcCtD
Rifaximin—Body temperature increased—Doxorubicin—pancreatic cancer	8.08e-05	0.000434	CcSEcCtD
Rifaximin—Abdominal pain—Doxorubicin—pancreatic cancer	8.08e-05	0.000434	CcSEcCtD
Rifaximin—Asthenia—Epirubicin—pancreatic cancer	7.92e-05	0.000426	CcSEcCtD
Rifaximin—Pruritus—Epirubicin—pancreatic cancer	7.81e-05	0.00042	CcSEcCtD
Rifaximin—Diarrhoea—Epirubicin—pancreatic cancer	7.56e-05	0.000406	CcSEcCtD
Rifaximin—Hypersensitivity—Doxorubicin—pancreatic cancer	7.53e-05	0.000405	CcSEcCtD
Rifaximin—Asthenia—Doxorubicin—pancreatic cancer	7.33e-05	0.000394	CcSEcCtD
Rifaximin—Dizziness—Epirubicin—pancreatic cancer	7.3e-05	0.000393	CcSEcCtD
Rifaximin—Pruritus—Doxorubicin—pancreatic cancer	7.23e-05	0.000389	CcSEcCtD
Rifaximin—Vomiting—Epirubicin—pancreatic cancer	7.02e-05	0.000378	CcSEcCtD
Rifaximin—Diarrhoea—Doxorubicin—pancreatic cancer	6.99e-05	0.000376	CcSEcCtD
Rifaximin—Rash—Epirubicin—pancreatic cancer	6.96e-05	0.000374	CcSEcCtD
Rifaximin—Dermatitis—Epirubicin—pancreatic cancer	6.96e-05	0.000374	CcSEcCtD
Rifaximin—Headache—Epirubicin—pancreatic cancer	6.92e-05	0.000372	CcSEcCtD
Rifaximin—Dizziness—Doxorubicin—pancreatic cancer	6.76e-05	0.000363	CcSEcCtD
Rifaximin—Nausea—Epirubicin—pancreatic cancer	6.56e-05	0.000353	CcSEcCtD
Rifaximin—Vomiting—Doxorubicin—pancreatic cancer	6.5e-05	0.000349	CcSEcCtD
Rifaximin—Rash—Doxorubicin—pancreatic cancer	6.44e-05	0.000347	CcSEcCtD
Rifaximin—Dermatitis—Doxorubicin—pancreatic cancer	6.44e-05	0.000346	CcSEcCtD
Rifaximin—Headache—Doxorubicin—pancreatic cancer	6.4e-05	0.000344	CcSEcCtD
Rifaximin—Nausea—Doxorubicin—pancreatic cancer	6.07e-05	0.000326	CcSEcCtD
